BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MM-121: Phase I started

Merrimack began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV MM-121 in combination with Erbitux cetuximab and irinotecan in about 45 patients. Sanofi has exclusive, worldwide rights to MM-121 from Merrimack...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >